PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Curr Opin HIV AIDS. Author manuscript; available in PMC 2010 May 1.
Published in final edited form as:
PMCID: PMC2760925
NIHMSID: NIHMS130842

Immunopathogenesis of Asymptomatic Chronic HIV Infection: The Calm before the Storm

Abstract

Purpose of review

HIV and pathogenic SIV infection are characterized by chronic immune activation. This review addresses the factors that influence immune activation and may thus determine the rate of disease progression during the asymptomatic period of HIV.

Recent findings

Immune activation stems from foreign antigen stimulation including HIV, microbial products and co-infections, and compensatory homeostatic mechanisms. Continuous immune stimulation creates a permissive environment for further viral replication, while temporarily allowing successful replenishment of the T cell pool. Type I IFN, microbial translocation, activated (but ineffective) effector T cells, unruly regulatory T cells and inadequate Th17 cells all play important roles in the cycle of activation, functional exhaustion and T cell death that leads to immunodeficiency.

Summary

The asymptomatic chronic phase of HIV infection is a dynamic balance between host and virus, the outcome of which determines an individual's course of disease. Evaluation of the factors that determine the immunologic threshold of disease progression could assist in designing therapeutic strategies including individualized timing of ART.

Keywords: Immune activation, Th17, type I interferons, homeostasis, T cells

Introduction

HIV infection is characterized by an initial, occasionally symptomatic acute phase followed by an asymptomatic period of variable length culminating in clinically evident immunodeficiency. Recent findings tying immune activation to disease pathogenesis have focused attention on earlier stages of HIV. A better understanding of factors that influence the precarious immunologic balance during early disease will assist development of targeted interventions, possibly including earlier or individualized timing of antiretroviral therapy (ART).

Immune Activation as the Protagonist in HIV Immunopathogenesis

Persistent immune activation is manifested by increased turnover of T cells, monocytes and NK cells, high levels of CD4 and CD8 T cell apoptosis and polyclonal B cell activation with hypergammaglobulinemia [1-8]. Immune activation is strongly predictive of HIV disease progression, even when measured prior to seroconversion [9,10]. Recent studies showing that IL-6, D-dimer and changes in C-Reactive Protein (CRP), all biomarkers associated with inflammation, predict mortality in HIV+ patients further revitalized interest in immune activation [11]. The specifics of how HIV hijacks the immune system into a perpetual cycle of activation and failure of viral control remain unclear.

The central role of immune activation in HIV pathogenesis has been demonstrated in studies of sooty mangabeys (SM) and African green monkeys (AGM), the natural hosts of simian immunodeficiency virus (SIV) infection. Sooty mangabeys develop high levels of SIV viremia without CD4 T cell losses or clinical disease. In contrast, rhesus macaques (RM) have lower or similar levels of SIV viremia but develop progressive CD4 T cell loss, leading to clinical manifestations similar to AIDS. The most evident difference between pathogenic (RM) and non-pathogenic (SM and AGM) SIV infection is the lack of immune activation in the latter [12].

Markers of immune activation in HIV include CD38 [13], HLA-DR [14], CD71 [9], intracellular Ki67 expression [3,7,15], total CD8 T cell counts and serum immunoglobulins [16,17], serum β2-microglobulin, soluble IL-2 receptor and neopterin [1,18,19]. Although many studies have found associations between immune activation and levels of HIV viremia [4,20], immune activation can be a stronger predictor of disease progression [1,13,18,21-23]. In one recent study, elite controllers (patients with plasma HIV RNA levels below the limit of detection in the absence of ART) with evidence of CD4 T cell depletion had elevated levels of predominantly CD8 T cell activation compared to controls or HIV+ patients on ART [24]. In contrast, patients with idiopathic CD4 lymphopenia (ICL) who have low CD4 T cells counts in the absence of HIV show evidence of immune activation in CD4 but not CD8 T cells [25]. These studies suggest that CD4 T cell activation may be at least partly related to lymphopenia-driven T cell proliferation [15,25,26]. Regardless of the stimulus, the presence of activated CD4 T cells appears to be essential for viral replication [27].

Continuous CD4 T cell loss and replenishment eventually leads to immunodeficiency as the regenerative capacity of weary naïve and central memory cells gradually dwindles despite apparent excess of homeostatic cytokines in the peripheral blood and lymphoid tissue [28-31]. This exhaustion of the T cell “supply” may be due to direct killing by the virus, virus-induced apoptosis, immunologic senescence and/or the architectural destruction of lymphoid organs from fibrosis induced by TGF-β and other cytokines [32,33] that may interfere with dendritic-T cell interactions and access to homeostatic cytokines.

This review addresses the different factors that determine the immunologic juncture at which the battle with HIV is lost and immunodeficiency ensues. We propose that some of these factors may become useful in assessing the “immune profile” or “immune score” of patients with asymptomatic HIV infection. Assessment of the immune score combined with age, genetic profiling [34-37] and co-morbidities such as cardiovascular disease or diabetes, could guide individualized therapeutic strategies prior to clinical manifestations of HIV immunodeficiency.

Gut: the veiled site of HIV pathogenesis

The gut is a key site of HIV infection and pathogenesis. Epithelial injury and CD4 T cell loss in the gut during acute infection may lead to dissemination of microbial products that fuel immune activation. Acute HIV infection results in enterocyte apoptosis and dysfunction, defects in mucosal repair, and earlier and more massive depletion of mucosal CD4 T cells [38,39] than in peripheral blood or lymphoid tissue [40-43]. This CD4 T cell depletion is likely due to a combination of direct viral infection, activation-induced cell death, and host-derived cytotoxic responses. Due to constant exposure to foreign antigens, a large proportion of gut CD4 T cells are activated and express CCR5, a co-receptor that enables HIV entry, providing fertile ground for HIV replication. In addition, as shown by Arthos et al [44], HIV may be actively recruiting T cells to the gut via α4β7, an integrin that mediates migration of lymphocytes to the gut. Engagement of α4β7 on CD4 T cells by gp120 leads to activation of lymphocyte function-associated molecule 1 (LFA-1) or αLβ2, facilitating formation of virologic synapses and increasing the efficiency of HIV infection [44].

The gut houses a large percentage of the total body CD4 T cells, consequently, losses in chronic asymptomatic HIV infection are probably not accurately reflected in peripheral blood. While the degree of CD4 T cell depletion in the gut has not been linked to disease prognosis per se, it may be indirectly enhancing immune activation in chronic HIV infection. An earlier study showed increased circulating lipopolysaccharide (LPS) and soluble CD14 (produced by macrophages in response to LPS) in HIV infected patients and SIV infected RM but not SM [45]. Interestingly, significant CD4 T cell depletion in the gut mucosa during acute SIV infection is seen in both SM and AGM [46,47]. Persistently elevated circulating LPS may lead to unabated stimulation of the innate immune system, with production of type I interferons and pro-inflammatory cytokines further augmenting immune activation and generating targets for HIV replication. A convincing experiment involving administration of LPS to AGM led to increases in both CD4 T cell activation and SIV viral load [48]. On the other hand, increased plasma LPS levels were also observed in ICL patients at levels similar to HIV+ patients with comparable CD4 T cell counts, suggesting that the HIV-induced apoptosis of enterocytes is not the main pathogenic mechanism [49]. Furthermore, CD8 T cell activation is not characteristic of ICL, indicating that elevated LPS levels are not always associated with CD8 T cell activation [24,49].

Why do SIV natural hosts have evidence of CD4 T cell depletion in the gut without enteropathy or circulating LPS? One piece of the puzzle may be Th17 cells, a subset of memory CD4 T cells that produce IL-17 and IL-22 in response to bacterial and fungal antigens [50]. The loss of Th17 cells in the gut may contribute to epithelial injury and enhance local inflammation and immune activation. Indeed, HIV+ patients and SIV-infected RM have significant depletion of gut Th17 CD4 T cells with an increase in Th1 CD4 T cells [50,51]. This may be due to preferential targeting of Th17 CD4 T cells, a shift toward Th1 differentiation, or infiltration of the gut by Th1 cells [51]. Notably, SM and AGM maintain Th17 cells in the gut despite mucosal CD4 T cell losses [50]. More importantly, in the SIV model, lack of Th17 response promoted S. typhimurium dissemination from the gut, tying together immunologic observations and known clinical consequences (recurrent Salmonella bacteremia) of HIV infection [52].

Several factors limit the execution and/or interpretation of studies involving the gut mucosa: the invasive nature of biopsies, differences in selection of biopsy sites, differences in methodology (flow cytometry or immunohistochemistry) and limited sampling material. A harmonized approach to studying the gut mucosa and measuring or estimating total body and total gut CD4 T cells would greatly advance this field.

The Elusive Role of Regulatory T cells in HIV Infection

The role of regulatory T cells (Tregs) in HIV disease progression is still unclear. As Tregs are capable of suppressing T cell activation, they could be of either benefit (suppressing over-activation, diminishing “bystander apoptosis” and T cell loss) or harm (suppressing HIV-specific T cell responses and hindering viral clearance) [53]. In support of the former, long-term non-progressors (LTNP) show greater maintenance of functional Tregs in chronic infection, with associated reduction in T cell activation [54,55]. Previous reports [56,57] have supported a strong correlation between Treg loss and increased CD4 T cell activation. Other studies found no association with disease progression or increased proportion of Tregs in advanced disease [58]. There is also disagreement over whether Tregs are spared [59] or targeted [57,60] by HIV.

Accumulation of Tregs has been reported in the lymph nodes [61] and gut of viremic patients [62]. After ART, gut Tregs appear to return to normal, suggesting that accumulation in tissues is related to HIV replication [62]. In AGM, an immediate emergence of Tregs is seen during acute SIV (non-pathogenic) infection, with concomitant TGF-β production dampening T cell activation [63]. In pigtail macaques, Tregs are depleted in the lamina propria shortly after pathogenic SIV infection, but are maintained or expand in peripheral blood and lymph tissue [64,65] possibly suppressing anti-viral responses. Interventional studies in non-pathogenic (AGM) and pathogenic (RM) animal models attempting to deplete (administration of Ontak) or block the function of (administration of anti-CTLA) Tregs in SIV infection have led to worsening immune activation and increasing viremia [48,51].

Three factors limit current investigations of Tregs in HIV: (i) phenotype does not equal function, as activated T cells can upregulate FoxP3, and TGF-β can induce FoxP3 and CD25 in naïve T cells without conferring suppressive function [66]; (ii) functional studies are difficult to perform due to cell number limitations; (iii) sampling of peripheral blood, which contains <5% of the lymphocyte population, may be suboptimal due to sequestration in lymphoid tissue. Considering the technical difficulties of studying small subsets of CD4 T cells in patients with significant CD4 lymphopenia, further Treg studies will depend on identification of markers that reliably predict function. Nevertheless, current evidence supports a potentially beneficial role of Treg in containing immune activation in HIV/SIV infection.

The Decisive Role of Type I Interferons in Chronic HIV Infection

In viral infections, type I interferons contribute to direct anti-viral activity and maturation of effector T cells [67,68]. Type I interferons also promote apoptosis of infected cells and suppress T and B cell development of mice in the thymus and bone marrow predominantly by interfering with IL-7 signaling [69-71]. IFNα is involved in the activation of T, NK, and B cell subsets and appears to be a significant link between innate and adaptive immunity in HIV disease pathogenesis [72]. Despite evidence for anti-HIV activity of type I interferons [73,74], the innate immune response during HIV infection may be the main driver of immune activation and disease progression [75]. Plasmacytoid dendritic cells (pDCs), in response to HIV virus or particles, produce type I interferons that lead to CD4 T cell apoptosis via TNF-related apoptosis inducing ligand (TRAIL) and expression of the tryptophan-catabolizing enzyme indoleamine-2,3-doxygenase (IDO). IDO inhibits TCR-triggered T cell proliferation [76] and can induce differentiation of naïve CD4 T cells into Tregs [77]. Boasso et al [76] showed that T cell activation occurs within 24h of in vitro infection of peripheral blood mononuclear cells (PBMC) – before any HIV-specific response can be generated, is associated with diminished proliferation to TCR signaling and can be reduced by more than 50% when IFNα was blocked. Despite increased circulating IFNα in patients with progressive disease, pDCs from HIV+ patients demonstrate a blunted IFN response upon stimulation in vitro [78]. This functional exhaustion of pDCs is the consequence of continuous in vivo stimulation as shown in HIV/HCV co-infected patients who have diminished in vitro pDC responses following treatment with exogenous IFN [79]. Supporting evidence comes also from microarray comparisons of activated CD4 T cells from HIV+ individuals with those from HIV- controls confirming markedly greater expression of IFN target genes in HIV [80].

In early pathogenic SIV infection of macaques, Mallaret et al [81] demonstrated an initial increase in peripheral pDCs, followed by recruitment to lymph tissue and concomitant depletion in peripheral blood. Depletion mirrored increases in plasma SIV-RNA and IFN-I, IDO, IFNγ, and IL-18 levels. Control of viremia with ART reduced the observed pDC tissue sequestration and dampened cytokine elevation. Consistent with HIV infection, in which IFN-α levels correspond to disease progression, SIV-infected RMs produce significantly higher IFN-α levels than SMs in response to SIV [82] (figure 1). SIV leads to pDC activation via TLR7 and TLR9 stimulation with subsequent IFNα production in human and RM PBMC that is markedly attenuated in SMs. This selective lack of innate response to acute SIV infection in SMs with muted NK cell activation, DC maturation and homing and abrogated INFα but not TNFα response warrants further investigation. These studies have clearly highlighted the role of pDCs and type I IFN in immune activation and their potential as therapeutic targets.

Figure 1
Summary of differences between nonpathogenic (sooty mangabeys) and pathogenic (rhesus macaques) SIV infection.

Effective CD8 T cells in HIV infection: A case for strength and youth

The role of CD8 T cells in controlling HIV and SIV viremia has been extensively studied. We selectively review publications of the past year that highlighted distinct features of CD8 T cells from LTNP, the potential role of inhibitory receptors and the presence of auto-reactive CD8 T cells in HIV+ patients.

The degree or polyfunctionality of anti-HIV specific CD8 T cell response, as measured by cytokine production, does not predict disease progression [83]. Nonetheless, the CD8 T cells of LTNPs appear to be different than those of progressors. Progressors initially mount a strong polyfunctional anti-HIV CD8 T cell response, but unlike LTNPs are unable to sustain it [83]. Previous studies have shown that HIV-specific CD8 T cells from LTNPs were more proliferative in response to HIV peptides or autologous CD4 T targets than those from progressors [84]. Most recently, CD8 T cells from LTNPs were shown to be more effective killers of HIV-infected CD4 T cells by release of perforin and granzyme B [85].

Another study highlighted a different aspect of the CD8 T cell advantage in elite controllers: telomeres in their HIV-specific CD8 T cells were significantly longer (and telomerase more active) compared to progressors [86]. CD8 T cells that have lost expression of CD27 and CD28 due to repeated stimulation and activation were incapable of reviving telomerase levels but were still capable of producing IFNγ and perforin upon stimulation. Thus, loss of telomerase may represent a state of end-stage differentiation and not functional exhaustion [86]. Enhanced T cell survival after TCR stimulation and γc cytokine signaling was also shown in the memory CD4 T cells of elite controllers compared to both progressors and HIV-uninfected controls and was found to be related to higher levels of phosporylated FOX3a, a transcription factor that has anti-proliferative and pro-apoptotic effects in its unphosphorylated, transciptionally active form [87,88]. Blocking FOXO3a by siRNA in this study improved T-cell survival after TCR stimulation [87].

Programmed death receptor (PD)-1 was first identified as a marker of T cell “exhaustion” correlating with HIV disease progression [89]. PD-1 was found to be over-expressed and associated with activation, impaired proliferation and reduced anti-viral activity in memory CD8 T cells of progressors as compared to LTNP [90]. Although blockade of PD-1 was shown to increase T cell survival [90], PD-1 is also expressed by activated, functional T cells, and may simply be an indicator of over-activation as opposed to the cause of T cell exhaustion [89,91]. However, treatment of SIV-infected RM in vivo with anti-PD-1 antibody improved CD8 T cell proliferation, increased SIV-specific CD8 T cell responses, decreased measurable viral load and improved survival [92]. These changes were seen primarily in TCR-triggered CD8 T cells, mitigating concerns about frank autoimmunity but evoking the possibility of selection of resistant viral mutants. Another inhibitory molecule, the T cell immunoglobulin and mucin domain–containing protein-3 (Tim-3), is up-regulated independently of PD-1 and is also associated with T cell dysfunction that can be partially reversed with blockade of its pathway [93]. The description of other inhibitory receptors on CD8 T cells that appear to co-regulate T cell exhaustion in chronic viral infections [94] as well as the presence of similar receptors on B lymphocytes in HIV infection [95] highlight the complexity of this field and the potential for multiple therapeutic targets.

Finally, self-reactive CD8 T cells may contribute to systemic immune activation in HIV. In mice, lymphopenia-induced proliferation can lead to loss of tolerance and auto-immunity [96]. In an intriguing study, Rawson et al [97] found that HIV infected patients have evidence of auto-reactive effector CD8 T cells specific for caspase-cleaved peptides from apoptotic T-cells. The number of effector CD8 T cells correlated with apoptotic CD4 T cells in HIV infected patients and decreased with ART.

The Role of Co-infections

Progression and transmission of HIV disease can be altered by bacterial and viral co-infections, which may actively participate in immune activation. Genital co-infections are associated with increased susceptibility to HIV, possibly due to local activation of Langerhan's cells enhancing transfer of HIV virions to CD4 T cells over viral degradation [98]. Genital HSV-2 infection also increases the local population of immature DC, leading to an influx of activated, CCR5+ CD4 T cell targets for HIV [99]. Infection with other viruses, especially adenovirus, has received attention following the STEP vaccine trial [100]. Perreau et al [101] found that adenovirus immune complexes (Ad5-IC) induce DC maturation and activation in vitro, resulting in increased production of TNFα and type I interferons. Ad5-IC significantly increased in vitro HIV infection, suggesting that adenovirus may create a “permissive environment” for HIV infection.

Mycobacterium tuberculosis (MTB) increases HIV-1 viral replication and immune activation at sites of infection. Interestingly, this increase in HIV replication is most pronounced in patients with normal CD4 T cell counts, suggesting that the synergy of the two infections may be dependent on the magnitude of immune response and activation [102]. Parasitic coinfections have also been shown to influence the natural history of HIV [103]. Rhesus macaques with schistosomiasis and SIV experience higher levels of SIV RNA than those infected with SIV alone [104]. In addition, treatment of lymphatic filariasis in HIV-infected patients led to decreases in plasma viremia, while treatment of A. lumbricoides led to CD4 T cell count increases [105,106].

Hepatitis C (HCV) co-infection appears to increase the percentage of activated, less mature CD8 but not CD4 T cells [107] and antiretroviral therapy interruption in hepatitis B or C co-infection is associated with non-opportunistic disease related death [108]. Further studies characterizing the interactions of HIV and chronic viral hepatitides and other latent chronic viral infections such as CMV and EBV will be critical in understanding their effects on HIV pathogenesis and disease prognosis.

Conclusion

Immune activation is at the crux of the complex interplay of innate and adaptive immunity throughout the asymptomatic stage of HIV infection (figure 2). Based on current evidence, the most effective preventive or therapeutic interventions may be those that maintain low levels of immune activation with either low (the elite controllers paradigm) or variable levels of HIV viremia (the sooty mangabey paradigm). Further elucidation of factors that influence the immunologic threshold to HIV disease progression may lead to therapeutic strategies that target immune activation and could include individualized timing of ART.

Figure 2
Immune activation in HIV infection results from dysregulated innate and adaptive immune responses to HIV, microbial products, co-infections and homeostatic signals.

Footnotes

Disclosure: E.S.F. and C.E.P. are participants in the Clinical Research Training Program, a public-private partnership supported jointly by the NIH and Pfizer Inc via a grant to the Foundation for NIH from Pfizer Inc.

References

1. Fahey JL, Taylor JM, Manna B, Nishanian P, Aziz N, Giorgi JV, Detels R. Prognostic significance of plasma markers of immune activation, HIV viral load and CD4 T-cell measurements. AIDS. 1998;12:1581–1590. [PubMed]
2. Hazenberg MD, Otto SA, Cohen Stuart JW, Verschuren MC, Borleffs JC, Boucher CA, Coutinho RA, Lange JM, Rinke de Wit TF, Tsegaye A, et al. Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection. Nat Med. 2000;6:1036–1042. [PubMed]
3. Hazenberg MD, Stuart JW, Otto SA, Borleffs JC, Boucher CA, de Boer RJ, Miedema F, Hamann D. T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART) Blood. 2000;95:249–255. [PubMed]
4. Kovacs JA, Lempicki RA, Sidorov IA, Adelsberger JW, Herpin B, Metcalf JA, Sereti I, Polis MA, Davey RT, Tavel J, et al. Identification of dynamically distinct subpopulations of T lymphocytes that are differentially affected by HIV. J Exp Med. 2001;194:1731–1741. [PMC free article] [PubMed]
5. Lane HC, Masur H, Edgar LC, Whalen G, Rook AH, Fauci AS. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1983;309:453–458. [PubMed]
6. Mohri H, Bonhoeffer S, Monard S, Perelson AS, Ho DD. Rapid turnover of T lymphocytes in SIV-infected rhesus macaques. Science. 1998;279:1223–1227. [PubMed]
7. Sachsenberg N, Perelson AS, Yerly S, Schockmel GA, Leduc D, Hirschel B, Perrin L. Turnover of CD4+ and CD8+ T lymphocytes in HIV-1 infection as measured by Ki-67 antigen. J Exp Med. 1998;187:1295–1303. [PMC free article] [PubMed]
8. Moir S, Malaspina A, Ogwaro KM, Donoghue ET, Hallahan CW, Ehler LA, Liu S, Adelsberger J, Lapointe R, Hwu P, et al. HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals. Proc Natl Acad Sci U S A. 2001;98:10362–10367. [PubMed]
9. Hazenberg MD, Otto SA, van Benthem BH, Roos MT, Coutinho RA, Lange JM, Hamann D, Prins M, Miedema F. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS. 2003;17:1881–1888. [PubMed]
10. van Asten L, Danisman F, Otto SA, Borghans JA, Hazenberg MD, Coutinho RA, Prins M, Miedema F. Pre-seroconversion immune status predicts the rate of CD4 T cell decline following HIV infection. AIDS. 2004;18:1885–1893. [PubMed]
11. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, Ledergerber B, Lundgren J, Neuhaus J, Nixon D, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5:e203. [PMC free article] [PubMed]
12. Silvestri G, Sodora DL, Koup RA, Paiardini M, O'Neil SP, McClure HM, Staprans SI, Feinberg MB. Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. Immunity. 2003;18:441–452. [PubMed]
13. Giorgi JV, Liu Z, Hultin LE, Cumberland WG, Hennessey K, Detels R. Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. 1993;6:904–912. [PubMed]
14. Lin RY, Nygren EJ, Valinsky JE, Ralph HE. T cell immunophenotypes and DR antigen expression in intravenous drug users. Relationship to human immunodeficiency virus serology. Int Arch Allergy Appl Immunol. 1988;87:263–268. [PubMed]
15. Anthony KB, Yoder C, Metcalf JA, DerSimonian R, Orenstein JM, Stevens RA, Falloon J, Polis MA, Lane HC, Sereti I. Incomplete CD4 T cell recovery in HIV-1 infection after 12 months of highly active antiretroviral therapy is associated with ongoing increased CD4 T cell activation and turnover. J Acquir Immune Defic Syndr. 2003;33:125–133. [PubMed]
16. Phillips AN, Sabin CA, Elford J, Bofill M, Lee CA, Janossy G. CD8 lymphocyte counts and serum immunoglobulin A levels early in HIV infection as predictors of CD4 lymphocyte depletion during 8 years of follow-up. AIDS. 1993;7:975–980. [PubMed]
17. Schechter MT, Craib KJ, Le TN, Montaner JS, Douglas B, Sestak P, Willoughby B, O'Shaughnessy MV. Susceptibility to AIDS progression appears early in HIV infection. AIDS. 1990;4:185–190. [PubMed]
18. Mildvan D, Spritzler J, Grossberg SE, Fahey JL, Johnston DM, Schock BR, Kagan J. Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV-1 infection. Clin Infect Dis. 2005;40:853–858. [PubMed]
19. Hofmann B, Wang YX, Cumberland WG, Detels R, Bozorgmehri M, Fahey JL. Serum beta 2-microglobulin level increases in HIV infection: relation to seroconversion, CD4 T-cell fall and prognosis. AIDS. 1990;4:207–214. [PubMed]
20. Sieg SF, Rodriguez B, Asaad R, Jiang W, Bazdar DA, Lederman MM. Peripheral S-phase T cells in HIV disease have a central memory phenotype and rarely have evidence of recent T cell receptor engagement. J Infect Dis. 2005;192:62–70. [PubMed]
21. Rodriguez B, Sethi AK, Cheruvu VK, Mackay W, Bosch RJ, Kitahata M, Boswell SL, Mathews WC, Bangsberg DR, Martin J, et al. Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. Jama. 2006;296:1498–1506. [PubMed]
22. Salazar-Gonzalez JF, Martinez-Maza O, Nishanian P, Aziz N, Shen LP, Grosser S, Taylor J, Detels R, Fahey JL. Increased immune activation precedes the inflection point of CD4 T cells and the increased serum virus load in human immunodeficiency virus infection. J Infect Dis. 1998;178:423–430. [PubMed]
23. Fahey JL, Taylor JM, Detels R, Hofmann B, Melmed R, Nishanian P, Giorgi JV. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med. 1990;322:166–172. [PubMed]
24. Hunt PW, Brenchley J, Sinclair E, McCune JM, Roland M, Page-Shafer K, Hsue P, Emu B, Krone M, Lampiris H, et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis. 2008;197:126–133. [PMC free article] [PubMed]• In a large cohort of elite controllers CD4 T cell counts inversely correlated with CD4 and CD8 T cell activation (HLA-DR+/CD38+) demonstrating the role of immune activation id CD4 depletion in the absence of detectable HIV viremia. In addition, elevated plasma LPS levels were seen in elite controllers which correlated with CD8 T cell activation. Notably, 79% of the patients were co-infected with HCV.
25. Zonios DI, Falloon J, Bennett JE, Shaw PA, Chaitt D, Baseler MW, Adelsberger JW, Metcalf JA, Polis MA, Kovacs SJ, et al. Idiopathic CD4+ lymphocytopenia: natural history and prognostic factors. Blood. 2008;112:287–294. [PubMed]• Long-term follow up of a cohort of 39 patients with ICL. Immunophenotyping revealed high levels of CD4 but not CD8 T cel activation highligting the role of lymphopenia in CD4 T cell activation.
26. Catalfamo M, Di Mascio M, Hu Z, Srinivasula S, Thaker V, Adelsberger J, Rupert A, Baseler M, Tagaya Y, Roby G, et al. HIV infection-associated immune activation occurs by two distinct pathways that differentially affect CD4 and CD8 T cells. Proc Natl Acad Sci U S A. 2008;105:19851–19856. [PubMed]
27. Klatt NR, Villinger F, Bostik P, Gordon SN, Pereira L, Engram JC, Mayne A, Dunham RM, Lawson B, Ratcliffe SJ, et al. Availability of activated CD4+ T cells dictates the level of viremia in naturally SIV-infected sooty mangabeys. J Cli Invest. 2008;118:2039–2049. [PMC free article] [PubMed]• Depletion of CD4 T cells with administration of humanized anti-CD4 mAb in SIV infected SM led to significant transient decreases of plasma SIV-RNA levels with rebound of viremia correlating strongly with the emergence of acivated and proliferating CD4 T cells.
28. Biancotto A, Grivel JC, Iglehart SJ, Vanpouille C, Lisco A, Sieg SF, Debernardo R, Garate K, Rodriguez B, Margolis LB, et al. Abnormal activation and cytokine spectra in lymph nodes of people chronically infected with HIV-1. Blood. 2007;109:4272–4279. [PubMed]
29. Fry TJ, Connick E, Falloon J, Lederman MM, Liewehr DJ, Spritzler J, Steinberg SM, Wood LV, Yarchoan R, Zuckerman J, et al. A potential role for interleukin-7 in T-cell homeostasis. Blood. 2001;97:2983–2990. [PubMed]
30. Napolitano LA, Grant RM, Deeks SG, Schmidt D, De Rosa SC, Herzenberg LA, Herndier BG, Andersson J, McCune JM. Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. Nat Med. 2001;7:73–79. [PubMed]
31. Okoye A, Meier-Schellersheim M, Brenchley JM, Hagen SI, Walker JM, Rohankhedkar M, Lum R, Edgar JB, Planer SL, Legasse A, et al. Progressive CD4+ central memory T cell decline results in CD4+ effector memory insufficiency and overt disease in chronic SIV infection. J Exp Med. 2007;204:2171–2185. [PMC free article] [PubMed]
32. Schacker TW, Reilly C, Beilman GJ, Taylor J, Skarda D, Krason D, Larson M, Haase AT. Amount of lymphatic tissue fibrosis in HIV infection predicts magnitude of HAART-associated change in peripheral CD4 cell count. Aids. 2005;19:2169–2171. [PubMed]
33. Estes JD, Wietgrefe S, Schacker T, Southern P, Beilman G, Reilly C, Milush JM, Lifson JD, Sodora DL, Carlis JV, et al. Simian immunodeficiency virus-induced lymphatic tissue fibrosis is mediated by transforming growth factor beta 1-positive regulatory T cells and begins in early infection. J Infect Dis. 2007;195:551–561. [PubMed]
34. Ahuja SK, Kulkarni H, Catano G, Agan BK, Camargo JF, He W, O'Connell RJ, Marconi VC, Delmar J, Eron J, et al. CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. Nat Med. 2008;14:413–420. [PMC free article] [PubMed]
35. Brass AL, Dykxhoorn DM, Benita Y, Yan N, Engelman A, Xavier RJ, Lieberman J, Elledge SJ. Identification of host proteins required for HIV infection through a functional genomic screen. Science. 2008;319:921–926. [PubMed]
36. Li H, Pascal V, Martin MP, Carrington M, Anderson SK. Genetic control of variegated KIR gene expression: polymorphisms of the bi-directional KIR3DL1 promoter are associated with distinct frequencies of gene expression. PLoS Genet. 2008;4:e1000254. [PMC free article] [PubMed]
37. Martin MP, Qi Y, Gao X, Yamada E, Martin JN, Pereyra F, Colombo S, Brown EE, Shupert WL, Phair J, et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet. 2007;39:733–740. [PubMed]
38. Dandekar S. Pathogenesis of HIV in the gastrointestinal tract. Curr HIV/AIDS Rep. 2007;4:10–15. [PubMed]
39. Zeitz M, Ullrich R, Schneider T, Kewenig S, Hohloch K, Riecken EO. HIV/SIV enteropathy. Ann N Y Acad Sci. 1998;859:139–148. [PubMed]
40. Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, Beilman GJ, Nguyen PL, Khoruts A, Larson M, Haase AT, et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med. 2004;200:749–759. [PMC free article] [PubMed]
41. Mehandru S, Poles MA, Tenner-Racz K, Horowitz A, Hurley A, Hogan C, Boden D, Racz P, Markowitz M. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med. 2004;200:761–770. [PMC free article] [PubMed]
42. Guadalupe M, Reay E, Sankaran S, Prindiville T, Flamm J, McNeil A, Dandekar S. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol. 2003;77:11708–11717. [PMC free article] [PubMed]
43. Schneider T, Jahn HU, Schmidt W, Riecken EO, Zeitz M, Ullrich R. Loss of CD4 T lymphocytes in patients infected with human immunodeficiency virus type 1 is more pronounced in the duodenal mucosa than in the peripheral blood. Berlin Diarrhea/Wasting Syndrome Study Group. Gut. 1995;37:524–529. [PMC free article] [PubMed]
44. Arthos J, Cicala C, Martinelli E, Macleod K, Van Ryk D, Wei D, Xiao Z, Veenstra TD, Conrad TP, Lempicki RA, et al. HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol. 2008;9:301–309. [PubMed]•• A tripeptide in the V2 loop of gp120 was found to bind α4β7 on CD4 T cells, an integrin which recruits T cells to the gut. In addition binding of α4β7 by gp120 activates LFA-1 which facilitates cell to cell spreading of HIV.
45. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, Kazzaz Z, Bornstein E, Lambotte O, Altmann D, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12:1365–1371. [PubMed]
46. Kaufmann DE, Kavanagh DG, Pereyra F, Zaunders JJ, Mackey EW, Miura T, Palmer S, Brockman M, Rathod A, Piechocka-Trocha A, et al. Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol. 2007;8:1246–1254. [PubMed]
47. Pandrea IV, Gautam R, Ribeiro RM, Brenchley JM, Butler IF, Pattison M, Rasmussen T, Marx PA, Silvestri G, Lackner AA, et al. Acute loss of intestinal CD4+ T cells is not predictive of simian immunodeficiency virus virulence. J Immunol. 2007;179:3035–3046. [PMC free article] [PubMed]
48. Pandrea I, Gaufin T, Brenchley JM, Gautam R, Monjure C, Gautam A, Coleman C, Lackner AA, Ribeiro RM, Douek DC, et al. Cutting Edge: Experimentally Induced Immune Activation in Natural Hosts of Simian Immunodeficiency Virus Induces Significant Increases in Viral Replication and CD4+ T Cell Depletion. J Immunol. 2008;181:6687–6691. [PMC free article] [PubMed]•• In this study, administration of LPS to AGM led to activation of CD4 T cells and transient increases in SIV viremia. Administration of Ontak (fusion protein of rIL2 with a diphteria toxin moiety) to AGM increased T cell activation and SIV viremia without clear evidence of Treg depletion.
49. Lee PI, Ciccone EJ, Read SW, Asher AI, Pitts R, Douek DC, Brenchley JM, Sereti I. Evidence for Translocation of Microbial Products in Patients with Idiopathic CD4 Lymphocytopenia. J Infect Dis. 2009 In Press. [PMC free article] [PubMed]• Increased plasma LPS levels are described in ICL patients without evidence of loss of Th17 CD4 T cells in peripheral blood. Data from gut biopsies of ICL patients were not available.
50. Brenchley JM, Paiardini M, Knox KS, Asher AI, Cervasi B, Asher TE, Scheinberg P, Price DA, Hage CA, Kholi LM, et al. Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood. 2008;112:2826–2835. [PubMed]• Preferential depletion of gut but not lung mucosal Th17 CD4 cells is described in HIV infected patients. In contrast, SM had preservation of Th17 CD4 T cells in the blood and GI tract highlighting an important difference of pathogenic versus non-pathogenic infection.
51. Cecchinato V, Trindade CJ, Laurence A, Heraud JM, Brenchley JM, Ferrari MG, Zaffiri L, Tryniszewska E, Tsai WP, Vaccari M, et al. Altered balance between Th17 and Th1 cells at mucosal sites predicts AIDS progression in simian immunodeficiency virus-infected macaques. Mucosa Immunol. 2008;1:279–288. [PMC free article] [PubMed]• In this study, Th1 and Th17 CD4 T cells were measured in acute and chronic SIV infection of RMs (pathogenic infection). Disproportional depletion of Th17 CD4 cells was observed in gut, peripheral blood and lymph nodes shortly after infection. The percentage of CD4/IL-17+ cells in all studied sites correlated negatively with plasma SIV RNA levels. Th1/Th17 imbalances may be important in SIV pathogenesis.
52. Raffatellu M, Santos RL, Verhoeven DE, George MD, Wilson RP, Winter SE, Godinez I, Sankaran S, Paixao TA, Gordon MA, et al. Simian immunodeficiency virus-induced mucosal interleukin-17 deficiency promotes Salmonella dissemination from the gut. Nat Med. 2008;14:421–428. [PMC free article] [PubMed]•• In this study, S. typhimurium in ligated ileal loops of healthy macaques led to a dominant Th17 response by gene expression profiling. SIV infection led to depletion of Th17 CD4 T cells and dissemination of S. typhimurium to mesenteric lymph nodes. The critical role of IL-17 in averting S. typhimurium dissemination was further demonstrated in IL-17R -/- mice.
53. Seddiki N, Kelleher AD. Regulatory T cells in HIV infection: who's suppressing what? Curr HIV/AIDS Rep. 2008;5:20–26. [PubMed]
54. Chase AJ, Yang HC, Zhang H, Blankson JN, Siliciano RF. Preservation of FoxP3+ regulatory T cells in the peripheral blood of human immunodeficiency virus type 1-infected elite suppressors correlates with low CD4+ T-cell activation. J Virol. 2008;82:8307–8315. [PMC free article] [PubMed]• In a cohort of 12 HIV+ LTNP, the authors found higher levels but comparable suppressive ability of Treg (CD25+/FoxP3+) cells compared to HIV+ progressors suggesting a protective role of Tregs against immune activation and T cell loss.
55. Jiao Y, Fu J, Xing S, Fu B, Zhang Z, Shi M, Wang X, Zhang J, Jin L, Kang F, et al. The decrease of regulatory T cells correlates with excessive activation and apoptosis of CD8(+) T cells in HIV-1-infected typical progressors, but not in long-term non-progressors. Immunology. 2008 [PubMed]
56. Eggena MP, Barugahare B, Jones N, Okello M, Mutalya S, Kityo C, Mugyenyi P, Cao H. Depletion of regulatory T cells in HIV infection is associated with immune activation. J Immunol. 2005;174:4407–4414. [PubMed]
57. Oswald-Richter K, Grill SM, Shariat N, Leelawong M, Sundrud MS, Haas DW, Unutmaz D. HIV infection of naturally occurring and genetically reprogrammed human regulatory T-cells. PLoS Biol. 2004;2:E198. [PMC free article] [PubMed]
58. Gaardbo JC, Nielsen SD, Vedel SJ, Ersboll AK, Harritshoj L, Ryder LP, Nielsen JO, Kolte L. Regulatory T cells in human immunodeficiency virus-infected patients are elevated and independent of immunological and virological status, as well as initiation of highly active anti-retroviral therapy. Clin Exp Immunol. 2008;154:80–86. [PubMed]
59. Selliah N, Zhang M, White S, Zoltick P, Sawaya BE, Finkel TH, Cron RQ. FOXP3 inhibits HIV-1 infection of CD4 T-cells via inhibition of LTR transcriptional activity. Virology. 2008;381:161–167. [PMC free article] [PubMed]
60. Jiang Q, Zhang L, Wang R, Jeffrey J, Washburn ML, Brouwer D, Barbour S, Kovalev GI, Unutmaz D, Su L. FoxP3+CD4+ regulatory T cells play an important role in acute HIV-1 infection in humanized Rag2-/-gammaC-/-mice in vivo. Blood. 2008;112:2858–2868. [PubMed]
61. Nilsson J, Boasso A, Velilla PA, Zhang R, Vaccari M, Franchini G, Shearer GM, Andersson J, Chougnet C. HIV-1-driven regulatory T-cell accumulation in lymphoid tissues is associated with disease progression in HIV/AIDS. Blood. 2006;108:3808–3817. [PubMed]
62. Epple HJ, Loddenkemper C, Kunkel D, Troger H, Maul J, Moos V, Berg E, Ullrich R, Schulzke JD, Stein H, et al. Mucosal but not peripheral FOXP3+ regulatory T cells are highly increased in untreated HIV infection and normalize after suppressive HAART. Blood. 2006;108:3072–3078. [PubMed]
63. Kornfeld C, Ploquin MJ, Pandrea I, Faye A, Onanga R, Apetrei C, Poaty-Mavoungou V, Rouquet P, Estaquier J, Mortara L, et al. Antiinflammatory profiles during primary SIV infection in African green monkeys are associated with protection against AIDS. J Clin Invest. 2005;115:1082–1091. [PMC free article] [PubMed]
64. Chase AJ, Sedaghat AR, German JR, Gama L, Zink MC, Clements JE, Siliciano RF. Severe depletion of CD4+ CD25+ regulatory T cells from the intestinal lamina propria but not peripheral blood or lymph nodes during acute simian immunodeficiency virus infection. J Virol. 2007;81:12748–12757. [PMC free article] [PubMed]
65. Estes JD, Li Q, Reynolds MR, Wietgrefe S, Duan L, Schacker T, Picker LJ, Watkins DI, Lifson JD, Reilly C, et al. Premature induction of an immunosuppressive regulatory T cell response during acute simian immunodeficiency virus infection. J Infect Dis. 2006;193:703–712. [PubMed]
66. Bostik P, Noble ES, Stephenson ST, Villinger F, Ansari AA. CD4+ T Cells from Simian Immunodeficiency Virus Disease-Resistant Sooty Mangabeys Produce More IL-2 Than Cells from Disease-Susceptible Species: Involvement of p300 and CREB at the Proximal IL-2 Promoter in IL-2 Up-Regulation. J Immunol. 2007;178:7720–7729. [PubMed]
67. Kolumam GA, Thomas S, Thompson LJ, Sprent J, Murali-Krishna K. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med. 2005;202:637–650. [PMC free article] [PubMed]
68. Muller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, Zinkernagel RM, Aguet M. Functional role of type I and type II interferons in antiviral defense. Science. 1994;264:1918–1921. [PubMed]
69. Baron ML, Gauchat D, La Motte-Mohs R, Kettaf N, Abdallah A, Michiels T, Zuniga-Pflucker JC, Sekaly RP. TLR Ligand-Induced Type I IFNs Affect Thymopoiesis. J Immunol. 2008;180:7134–7146. [PubMed]
70. Demoulins T, Abdallah A, Kettaf N, Baron ML, Gerarduzzi C, Gauchat D, Gratton S, Sekaly RP. Reversible blockade of thymic output: an inherent part of TLR ligand-mediated immune response. J Immunol. 2008;181:6757–6769. [PubMed]
71. Lin Q, Dong C, Cooper MD. Impairment of T and B cell development by treatment with a type I interferon. J Exp Med. 1998;187:79–87. [PMC free article] [PubMed]
72. Boasso A, Herbeuval JP, Hardy AW, Anderson SA, Dolan MJ, Fuchs D, Shearer GM. HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells. Blood. 2007;109:3351–3359. [PubMed]
73. Lane HC, Davey V, Kovacs JA, Feinberg J, Metcalf JA, Herpin B, Walker R, Deyton L, Davey RT, Jr, Falloon J, et al. Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial. Ann Intern Med. 1990;112:805–811. [PubMed]
74. Neumann A, Polis M, Rozenberg L, Jackson J, Reitano K, McLaughlin M, Koratich C, Dewar R, Masur H, Haagmans B, et al. Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients. AIDS. 2007;21:1855–1865. [PubMed]
75. Boasso A, Shearer GM. Chronic innate immune activation as a cause of HIV-1 immunopathogenesis. Clin Immunol. 2008;126:235–242. [PMC free article] [PubMed]
76. Boasso A, Hardy AW, Anderson SA, Dolan MJ, Shearer GM. HIV-induced type I interferon and tryptophan catabolism drive T cell dysfunction despite phenotypic activation. PLoS ONE. 2008;3:e2961. [PMC free article] [PubMed]
77. Manches O, Munn D, Fallahi A, Lifson J, Chaperot L, Plumas J, Bhardwaj N. HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism. J Clin Invest. 2008;118:3431–3439. [PMC free article] [PubMed]• In an in vitro system, pDC stimulated by HIV induced differentiation of naïve CD4 T cells into Tregs with suppressive function. This was primarily dependent on IDO induction via TLR7 triggering by genomic HIV RNA and not on IFNα production.
78. Lehmann C, Harper JM, Taubert D, Hartmann P, Fatkenheuer G, Jung N, van Lunzen J, Stellbrink HJ, Gallo RC, Romerio F. Increased interferon alpha expression in circulating plasmacytoid dendritic cells of HIV-1-infected patients. J Acquir Immune Defic Syndr. 2008;48:522–530. [PubMed]
79. Tilton JC, Manion MM, Luskin MR, Johnson AJ, Patamawenu AA, Hallahan CW, Cogliano-Shutta NA, Mican JM, Davey RT, Jr, Kottilil S, et al. Human immunodeficiency virus viremia induces plasmacytoid dendritic cell activation in vivo and diminished alpha interferon production in vitro. J Virol. 2008;82:3997–4006. [PMC free article] [PubMed]
80. Sedaghat AR, German J, Teslovich TM, Cofrancesco J, Jr, Jie CC, Talbot CC, Jr, Siliciano RF. Chronic CD4+ T-cell activation and depletion in human immunodeficiency virus type 1 infection: type I interferon-mediated disruption of T-cell dynamics. J Virol. 2008;82:1870–1883. [PMC free article] [PubMed]
81. Malleret B, Maneglier B, Karlsson I, Lebon P, Nascimbeni M, Perie L, Brochard P, Delache B, Calvo J, Andrieu T, et al. Primary infection with simian immunodeficiency virus: plasmacytoid dendritic cell homing to lymph nodes, type I interferon, and immune suppression. Blood. 2008;112:4598–4608. [PubMed]
82. Mandl JN, Barry AP, Vanderford TH, Kozyr N, Chavan R, Klucking S, Barrat FJ, Coffman RL, Staprans SI, Feinberg MB. Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Nat Med. 2008;14:1077–1087. [PubMed]•• The authors show that SIV-infected SMs have a muted innate immune response to SIV infection and their pDCs produce less IFN-α in response to SIV and other TLR7 and 9 ligands compared to RMs. The mechanisms underlying this selective absence of innate response to SIV in SMs is still unclear.
83. Schellens IM, Borghans JA, Jansen CA, De Cuyper IM, Geskus RB, van Baarle D, Miedema F. Abundance of early functional HIV-specific CD8+ T cells does not predict AIDS-free survival time. PLoS ONE. 2008;3:e2745. [PMC free article] [PubMed]
84. Migueles SA, Laborico AC, Shupert WL, Sabbaghian MS, Rabin R, Hallahan CW, Van Baarle D, Kostense S, Miedema F, McLaughlin M, et al. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol. 2002;3:1061–1068. [PubMed]
85. Migueles SA, Osborne CM, Royce C, Compton AA, Joshi RP, Weeks KA, Rood JE, Berkley AM, Sacha JB, Cogliano-Shutta NA, et al. Lytic Granule Loading of CD8(+) T Cells Is Required for HIV-Infected Cell Elimination Associated with Immune Control. Immunity. 2008 [PMC free article] [PubMed]• This paper demonstrates that HIV-specific CD8 T cells from LTNP efficiently eliminate HIV-infected target cells by granzyme-B mediated killing.
86. Plunkett FJ, Franzese O, Finney HM, Fletcher JM, Belaramani LL, Salmon M, Dokal I, Webster D, Lawson AD, Akbar AN. The loss of telomerase activity in highly differentiated CD8+CD28-CD27- T cells is associated with decreased Akt (Ser473) phosphorylation. J Immunol. 2007;178:7710–7719. [PubMed]
87. van Grevenynghe J, Procopio FA, He Z, Chomont N, Riou C, Zhang Y, Gimmig S, Boucher G, Wilkinson P, Shi Y, et al. Transcription factor FOXO3a controls the persistence of memory CD4(+) T cells during HIV infection. Nat Med. 2008;14:266–274. [PubMed]• FOXO3a is a transcription factor that is active in its unphosphorylated form promoting apoptosis via FasL, Bim and p130. High levels of phosphorylated FOXO3a were found in this study in memory CD4 T cells of elite controllers and were correlated with improved survival after T cell proliferation.
88. Riou C, Yassine-Diab B, Van grevenynghe J, Somogyi R, Greller LD, Gagnon D, Gimmig S, Wilkinson P, Shi Y, Cameron MJ, et al. Convergence of TCR and cytokine signaling leads to FOXO3a phosphorylation and drives the survival of CD4+ central memory T cells. J Exp Med. 2007;204:79–91. [PMC free article] [PubMed]
89. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, Mackey EW, Miller JD, Leslie AJ, DePierres C, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature. 2006;443:350–354. [PubMed]
90. Zhang JY, Zhang Z, Wang X, Fu JL, Yao J, Jiao Y, Chen L, Zhang H, Wei J, Jin L, et al. PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressors. Blood. 2007;109:4671–4678. [PubMed]
91. Trautmann L, Janbazian L, Chomont N, Said EA, Gimmig S, Bessette B, Boulassel MR, Delwart E, Sepulveda H, Balderas RS, et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med. 2006;12:1198–1202. [PubMed]
92. Velu V, Titanji K, Zhu B, Husain S, Pladevega A, Lai L, Vanderford TH, Chennareddi L, Silvestri G, Freeman GJ, et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature. 2008 [PMC free article] [PubMed]•• In this study, anti-PD-1 anibody was administered to SIV-infected macaques and led to rapid expansion and functional improvement of SIV-specific CD8 T cells with some evidence of B cell proliferation and increases in SIV envelope-specific Ab. Decreases in plasma SIV-RNA levels and improved survival were observed in treated animals.
93. Jones RB, Ndhlovu LC, Barbour JD, Sheth PM, Jha AR, Long BR, Wong JC, Satkunarajah M, Schweneker M, Chapman JM, et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med. 2008;205:2763–2779. [PMC free article] [PubMed]• The authors describe the over-expression of a novel inhibitory molecule, Tim-3, on T cells from HIV+ patients. Expression of Tim-3 correlated with both CD38 and viral load and was independent of PD-1. HIV-specific T cells expressing Tim-3 had evidence of functional exhaustion which was partially restored by Tim-3 blockade.
94. Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, Polley A, Betts MR, Freeman GJ, Vignali DA, Wherry EJ. Coregulation of CD8(+) T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol. 2008 [PMC free article] [PubMed]• Multiple inhibitory receptors (PD-1, LAG-3, CD160 and 2B4) were studied in a mouse model of LCMV and their expression patterns were correlated with disease severity. Greater improvement of CD8 T cell function was achieved with co-blockade of PD-L1 and LAG-3. This study reveals the complexity of inhibitory receptor biology and the possibility of multi-targeted therapeutic approaches.
95. Moir S, Ho J, Malaspina A, Wang W, DiPoto AC, O'Shea MA, Roby G, Kottilil S, Arthos J, Proschan MA, et al. Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J Exp Med. 2008;205:1797–1805. [PMC free article] [PubMed]
96. Khiong K, Murakami M, Kitabayashi C, Ueda N, Sawa S, Sakamoto A, Kotzin BL, Rozzo SJ, Ishihara K, Verella-Garcia M, et al. Homeostatically proliferating CD4 T cells are involved in the pathogenesis of an Omenn syndrome murine model. J Clin Invest. 2007;117:1270–1281. [PMC free article] [PubMed]
97. Rawson PM, Molette C, Videtta M, Altieri L, Franceschini D, Donato T, Finocchi L, Propato A, Paroli M, Meloni F, et al. Cross-presentation of caspase-cleaved apoptotic self antigens in HIV infection. Nat Med. 2007;13:1431–1439. [PubMed]• In this study, proteomic analysis of apoptotic T cells identified caspase-cleaved fragments of cellular proteins that contain epitopes, which can be recognized by CD8 T cells during HIV infection. The frequencies of these CD8 T cells correlate with circulating apoptotic CD4+ T cells in HIV-1–infected individuals. The authors propose that these self-reactive effector CD8 T cells may contribute to the systemic immune activation during chronic HIV infection. Further studies will be needed to corroborate these findings.
98. de Jong MA, de Witte L, Oudhoff MJ, Gringhuis SI, Gallay P, Geijtenbeek TB. TNF-alpha and TLR agonists increase susceptibility to HIV-1 transmission by human Langerhans cells ex vivo. J Clin Invest. 2008;118:3440–3452. [PMC free article] [PubMed]
99. Rebbapragada A, Wachihi C, Pettengell C, Sunderji S, Huibner S, Jaoko W, Ball B, Fowke K, Mazzulli T, Plummer FA, et al. Negative mucosal synergy between Herpes simplex type 2 and HIV in the female genital tract. AIDS. 2007;21:589–598. [PubMed]
100. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008;372:1881–1893. [PMC free article] [PubMed]
101. Perreau M, Pantaleo G, Kremer EJ. Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells. J Exp Med. 2008;205:2717–2725. [PMC free article] [PubMed]• In an in vitro system, Ad5 IC compared with Ad5 vector alone induced more pronounced DC maturation with higher levels of type I IFN and TNF production, more robust Ad5-specific CD8 T cell responses and enhancement of HIV infection. These data may assist in interpretation of the STEP trial findings.
102. Toossi Z, Mayanja-Kizza H, Hirsch CS, Edmonds KL, Spahlinger T, Hom DL, Aung H, Mugyenyi P, Ellner JJ, Whalen CW. Impact of tuberculosis (TB) on HIV-1 activity in dually infected patients. Clin Exp Immunol. 2001;123:233–238. [PubMed]
103. Borkow G, Bentwich Z. HIV and helminth co-infection: is deworming necessary? Parasite Immunol. 2006;28:605–612. [PubMed]
104. Ayash-Rashkovsky M, Chenine AL, Steele LN, Lee SJ, Song R, Ong H, Rasmussen RA, Hofmann-Lehmann R, Else JG, Augostini P, et al. Coinfection with Schistosoma mansoni reactivates viremia in rhesus macaques with chronic simian-human immunodeficiency virus clade C infection. Infect Immun. 2007;75:1751–1756. [PMC free article] [PubMed]
105. Nielsen NO, Simonsen PE, Dalgaard P, Krarup H, Magnussen P, Magesa S, Friis H. Effect of diethylcarbamazine on HIV load, CD4%, and CD4/CD8 ratio in HIV-infected adult Tanzanians with or without lymphatic filariasis: randomized double-blind and placebo-controlled cross-over trial. Am J Trop Med Hyg. 2007;77:507–513. [PubMed]
106. Walson JL, Otieno PA, Mbuchi M, Richardson BA, Lohman-Payne B, Macharia SW, Overbaugh J, Berkley J, Sanders EJ, Chung MH, et al. Albendazole treatment of HIV-1 and helminth co-infection: a randomized, double-blind, placebo-controlled trial. AIDS. 2008;22:1601–1609. [PMC free article] [PubMed]
107. Kovacs A, Al-Harthi L, Christensen S, Mack W, Cohen M, Landay A. CD8(+) T cell activation in women coinfected with human immunodeficiency virus type 1 and hepatitis C virus. J Infect Dis. 2008;197:1402–1407. [PMC free article] [PubMed]
108. Tedaldi E, Peters L, Neuhaus J, Puoti M, Rockstroh J, Klein MB, Dore GJ, Mocroft A, Soriano V, Clotet B, et al. Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. Clin Infect Dis. 2008;47:1468–1475. [PubMed]